PASADENA, Calif.--(BUSINESS WIRE)--Nov. 17, 2004--Sanguine Corp. (the company) (OTC BB: SGNC - News), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells, announced its product, PHER-O2 has successfully completed animal toxicity & efficacy trials at the University of Alberta in Edmonton, Canada. The company expects to have additional information related to human testing by the university in the next few weeks.
Thomas Drees, Ph.D., chairman and CEO of Sanguine Corp., stated, "Diabetes is the fastest growing chronic disease in the U.S. and the world. Islet cells produce insulin, which diabetics lack. We are excited to aid the University of Alberta in their endeavors with a supply of PHER-O2."

Sanguine Corp. is a development-stage company focused on the research and development of PHER-O2, a synthetic red blood cell product with potential applications in a variety of specialties, including transfusions, CAT scans, cardioplegia and the treatment of heart attacks, strokes, head and neck tumors, and hemorrhagic shock. The company is also developing nonmedical applications for its perfluorocarbon (PFC) product.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.

Contact:
Sanguine Corp.
Michael Dancy, 801-746-3570 (Investor Relations)
medancy@allwest.net
www.sanguine-corp.com

-----------------------------------------------

Sanguine is Discussing a Project with the U.S. Army Medical Corps
Tuesday November 9, 6:30 am ET

PASADENA, Calif.--(BUSINESS WIRE)--Nov. 9, 2004--Sanguine Corp. (OTC BB: SGNC - News), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells, announced that it is conferring with the U.S. Army Medical Corps to develop a "golden hour" medical kit using PHER-O2. Such a kit could allow self-transfusion on the battlefield, thus helping to prevent bleeding to death, which is a major cause of fatality in combat, and which continues to be the case in Iraq, despite the improvements in front line medical care.
Thomas Drees, Ph.D., chairman and CEO of Sanguine Corp., stated, "In treating battlefield injuries, time is often critical to survivability. If a 'golden hour' kit can be developed, either self-transfusion or field transfusion by a medic could allow a wounded soldier a better opportunity at survival. This could be possible since PHER-O2 does not require refrigeration nor type and crossmatching, which is necessary with packed red cells."

--------------------------------------------------

Sanguine's PHER-O2 is in Trials with Virginia Commonwealth University for the U.S. Navy
Monday November 1, 6:30 am ET

PASADENA, Calif.--(BUSINESS WIRE)--Nov. 1, 2004--Sanguine Corp. (OTCBB: SGNC - News), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells, today announced that its synthetic red blood cell substitute, PHER-O2, is being used in trials conducted by Virginia Commonwealth University for the U.S. Navy on submarine crew and deep sea diving oxygenation treatment of the bends.
Thomas Drees, Ph.D., chairman and CEO of Sanguine Corp., noted, "In the medical treatment of the bends, the doctor typically will first treat immediate life threats, such as breathing problems or shock, if present. The diver will need high-flow oxygen and IV fluids. Blood and urine will be sent for laboratory tests to assess any blood clotting problems and hydration status. Additionally, the diver will need to go to a hyperbaric chamber for recompression. During this process the chamber becomes pressurized with air and oxygen based on prearranged protocols to simulate pressure depths of 30-60 feet. Typical dives last 140-270 minutes, but may last longer. At this depth or chamber pressures, bubbles are reduced in size or reabsorbed to ensure adequate blood flow. Recompression prevents further bubble formation and provides high amounts of oxygen to the injured tissues. Further treatments depend on how the diver responds to the initial treatment. The work under way with the U.S. Navy and Virginia Commonwealth University is an effort to use PHER-O2 in conjunction with increasing the blood oxygen levels in patients with the bends. One of the goals is to better enable the quick ascent of divers working on military operations."

Sanguine Corp. is a development-stage company focused on the research and development of PHER-O2, a synthetic red blood cell product with potential applications in a variety of specialties, including: transfusions, CAT scans, cardioplegia and the treatment of heart attacks, strokes, head and neck tumors, and hemorrhagic shock. The company is also developing non-medical applications for its perfluorocarbon (PFC) product.

----------------------------------------------------------

Sanguine's PHER-O2 Synthetic Red Blood Cell is Being Tested by Three Medical Schools in the United States and Canada
Tuesday October 26, 6:30 am ET

PASADENA, Calif.--(BUSINESS WIRE)--Oct. 26, 2004--Sanguine Corp. (OTCBB: SGNC - News), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells, today announced that its synthetic red blood cell substitute, PHER-O2, is being tested in various phases of animal toxicity trials being conducted by three medical schools in the United States and Canada. The focus of studies with PHER-O2 is its effectiveness in perfusion for pancreas preservation for transplantation. The universities include the University of Chicago, the University of Maryland and the University of Alberta (Canada).
These perfusion studies are aimed at enhancement of islets used in transplant action as amelioration for diabetes, the fastest growing disease in the United States and the world. Islet transplantation is done to improve human insulin production in Type 2 or adult onset diabetes.

Thomas Drees, Ph.D., chairman and CEO of Sanguine Corp., stated, "PHER-O2's predecessor, Fluosol DA, which is the only oxygen-carrying synthetic red blood cell substitute to have received FDA approval, underwent 34 animal trials as part of its FDA approval. We expect the trials conducted by the medical schools will, in part, satisfy some of the FDA testing requirements needed for Sanguine's animal trials."

Dr. Drees continued, "The successful completion of the studies will give Sanguine valuable information needed to commence our animal toxicity testing. We plan to begin the testing with a highly respected facility, which we are in the process of selecting."

------------------------------------------------------------

Form 8-K for SANGUINE CORP

7-Oct-2004

Other Events, Financial Statements and Exhibits

Item 8.01. Other.
(a) On September 29, 2004, in order to restructure our financial statements to better enable us to commence animal testing of PHER-02, our developmental synthetic red blood cell product, the following was accomplished:

1. The Convertible Note executed in favor of Barbara R. Mittman on March 19, 2002, in the amount of $3,750.00, together with accrued interest, was converted to 97,102 shares of common stock of the Company.

2. The Convertible Note executed in favor of First York Partners, Inc. on March 15, 2002, in the amount of $25,000, together with accrued interest, was converted to 676,800 shares of common stock of the Company.

3. The Exclusive License Agreement dated February 15, 2002, with Ascendiant-Asia, LLC, a Nevada limited liability corporation ("Ascendiant-Asia"), was terminated for failure to meet minimum production or to pay royalties due pursuant to the terms of the License Agreement.

4. The Exclusive License Agreement dated April 1, 2002, with Ascendiant-South America, LLC, a Nevada limited liability corporation ("Ascendiant-South America"), was terminated for failure to meet minimum production or to pay royalties due pursuant to the terms of the License Agreement.

5. The Letter Agreement executed in favor of Ascendiant Capital Group, LLC ("Ascendiant"), pursuant to which Ascendiant loaned $12,000 to the Company, together with accrued interest, was converted to 228,666 shares of common stock of the Company; and for previously extending the term of the Letter Agreement, an additional Common Stock Purchase Warrant was granted to Ascendiant for the option to purchase 30,000 shares of common stock of the Company that are "restricted securities" under Rule 144 of the Securities and Exchange Commission.

6. Thomas C. Drees, Ph.D., MBA, the Company's President, CEO and a Director agreed to exchange $1,264,160 of debt owed to him by the Company for 31,604,000 shares of the Company's common stock that are "restricted securities" under Rule 144 of the Securities and Exchange Commission; and Dr. Drees also agreed to contribute to capital his accrued salary of $497,500 and interest on the debt owed to him by the Company in the amount of $453,630, together with any interest on any of these amounts since June 30, 2004.

7. The Anthony and Audrey Hargreaves Trust (the "Trust") agreed to exchange $36,984 of debt owed by the Company to Mr. Hargreaves prior to his death for 924,600 shares of the Company's common stock that are "restricted securities" under Rule 144 of the Securities and Exchange Commission; and the Trust also agreed to contribute to capital Mr. Hargreaves' accrued salary of $276,500, together with any interest on any of these amounts since June 30, 2004.

(b) Pursuant to a Confidential Offering Memorandum ("Offering Memorandum") dated May 18, 2000, the Company offered and sold 1,635,970 Units consisting of two (2) shares of common stock of the Company and one (1) redeemable common stock purchase warrant to purchase one (1) share of the Company's common stock (the "Warrants"). In addition to the Warrants issued to the subscribers to the Offering Memorandum, 163,597 Warrants were issued to the Company's Placement Agent as a portion of their commission, for a total of 1,799,567 Warrants issued pursuant to the Offering Memorandum. All of the Warrants, except the 163,597 Placement Agent Warrants that had been exercised, expired on August 29, 2004.

Item 9.01. Financial Statements, Pro Forma Financial Information and Exhibits.
(a) Financial Statements of Businesses Acquired.

(b) Pro Forma Financial Information.

None; not applicable.

Exhibits.

Exhibit
Number Description
------ -----------

99.1 Thomas C. Drees Letter Agreement

99.2 Anthony and Audrey Hargreaves Trust Letter Agreement

99.3 Ascendiant-Asia LLC Notice of Termination

99.4 Ascendiant-South America LLC Notice of Termination

99.5 Press Release

----------------------------------------------------------------

SGNC - SANGUINE (OTCBB)
Date Open High Low Last Change Volume % Change
11/17/04 0.2600 0.4300 0.2500 0.3900 +0.1550 1736326 +65.96%

Composite Indicator
Trend Spotter TM Buy

Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Buy

Short Term Indicators Average: 100% - Buy
20-Day Average Volume - 203020

Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy

Medium Term Indicators Average: 100% - Buy
50-Day Average Volume - 118226

Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy

Long Term Indicators Average: 100% - Buy
100-Day Average Volume - 72523

Overall Average: 100% - Buy

http://quote.barchart.com/texadv.asp?sym=SGNC
http://stockcharts.com/def/servlet/SC.web?c=sgnc,uu[m,a]daclyyay[pb50!b20][vc60][iUb14!La12,26,9]&pref=G

------------------
'wid ma mind on ma money an' ma money on ma MIND!!!!!!!

Do Da Due!!!

RUFF!!!